Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)
Breaking news: RNAi can significantly inhibit hepatitis B and is expected to become a new treatment for HBV
Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition
Will the mRNA vaccine become the "savior" of COVID-19?
mRNA-1647，the first infectious disease mRNA vaccine to enter the second phase of research
FDA approves first RNAi treatment for inherited rare diseases
bioRxiv.: Scientists Find siRNA drugs that may inhibit SARS-CoV-2
Cell Immunity: SARS-CoV-2 vaccines status
Onpattro, The First FDA-approved RNAi Drug
SARS-CoV-2 is undergoing mutations. Does the vaccine still work?